Oral GLIX1 for Recurrent or Progressive High-grade Glioma

This study focuses on a potential treatment for adults with recurrent or progressive high-grade glioma, a type of brain tumor that is aggressive and often comes back or worsens over time. The current treatment options for this condition are limited, making the search for new therapies crucial. The study is investigating a drug called GLIX1, a small molecule that is taken orally. GLIX1 works by enhancing the activity of an enzyme called TET2, which can lead to the death of cancer cells, particularly in high-grade glioma where this enzyme's activity is typically low. The study is designed to find the maximum safe dose of GLIX1 and to understand its safety profile. Participants will take the drug orally, and the study will monitor for any adverse events. The primary outcomes of the study are to determine the maximum tolerated dose of GLIX1 and to evaluate the percentage of participants who experience treatment-emergent adverse events. These results will help researchers understand the safety and potential effectiveness of GLIX1 in treating high-grade glioma.